Why is Uniqure NV stock gaining today?

Uniqure NV stock rose 2.4% in pre-open trading today after William Blair initiated coverage of the gene therapy company with an "Outperform" rating, joining an already heavily bullish analyst community that now counts 11 buy-equivalent ratings and just one hold, with no sell recommendations on record.

The William Blair initiation adds institutional weight to a thesis centered on uniQure’s clinical pipeline. The company reached alignment with the FDA in July 2026 on an accelerated Biologics License Application pathway for AMT-130, its investigational gene therapy targeting Huntington’s disease, a development that has been a key driver of the stock’s remarkable recovery — up roughly 175% over the past 12 months from a 52-week low of $8.73.

The company also holds a strong cash position and amended its loan facility with Hercules Capital to extend its financial runway.

The broader market offered little directional help today, with the S&P 500 essentially flat and the Nasdaq marginally in the red, underscoring that today’s move in QURE is a company-specific event. Within the gene therapy and rare-disease biotech space, peers such as REGENXBIO and Voyager Therapeutics have similarly benefited from renewed investor interest in the sector following improved regulatory clarity.

Taken together, the William Blair initiation served as the immediate spark for today’s pre-market gain, amplified by an overwhelmingly constructive analyst backdrop and the ongoing narrative around AMT-130’s path toward potential approval — a combination that continues to attract buyers even as the stock trades well off its 52-week high of $71.50.